Bio Pharma Dive
JUNE 30, 2025
The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.
Pharmaceutical Technology
JUNE 30, 2025
The FDA has approved Sobi's Gamifant (emapalumab) to treat adults and children with HLH/MAS associated with Still’s disease, including sJIA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT News
JUNE 30, 2025
American medical research is a unique source of national pride and reputation — some would say the United States’ most important export. Yet Secretary of Health and Human Services Robert F. Kennedy Jr. seems bent on destroying our greatest successes. As the latest strike, Kennedy is going after the publications that disseminate medical research.
Scienmag
JUNE 30, 2025
A groundbreaking advancement in breast cancer detection has emerged from a team of researchers led by Caltech, unveiling an innovative imaging technique that promises to transform diagnostic practices. This novel method harnesses the power of photoacoustic computed tomography (PACT), an approach that combines the penetrating capabilities of sound with the molecular sensitivity of light, providing an imaging experience that is not only safer and more comfortable for patients but also potentially
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
STAT News
JUNE 30, 2025
A new blood test could predict preeclampsia as early as the first trimester. In a new study, researchers successfully predicted the early-onset subtype of the prenatal condition up to five months before clinical diagnosis. The findings are being presented Monday during the annual meeting of the European Society of Human Reproduction and Embryology, in Paris.
Scienmag
JUNE 30, 2025
In the evolving landscape of cancer biology, the tumor suppressor protein p53 stands as a pivotal guardian of cellular integrity, orchestrating responses to DNA damage and preventing oncogenic transformation. However, mutations within the TP53 gene—a hallmark in a vast majority of human cancers—transform this protective sentinel into a driver of malignancy.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
JUNE 30, 2025
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Cidara and hVIVO report positive results in flu prevention study by John Pinching | 30th Jun 2025 | News New data show strong efficacy of CD388 in phase 2b trial Cidara Therapeutics and hVIVO have announced encouraging topline results from a global phase 2b field study evaluating CD388, a drug-Fc conjuga
pharmaphorum
JUNE 30, 2025
There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.
Pharma Times
JUNE 30, 2025
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs UCB reports success in phase 3 study of fenfluramine for CDD by John Pinching | 30th Jun 2025 | News Positive trial results offer hope for those with ultra-rare epileptic disorder UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and
Scienmag
JUNE 30, 2025
In the intricate workings of the brain, the circadian rhythm governs countless physiological processes, orchestrated by a complex interplay of molecular components. Among these, the transcription factor CLOCK has long been recognized as a crucial regulator, ubiquitously expressed across tissues to maintain robust circadian cycles. Yet, recent groundbreaking research reveals a layer of complexity previously unappreciated: human-specific expression of CLOCK within the neocortex, pointing toward an
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
pharmaphorum
JUNE 30, 2025
With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.
Scienmag
JUNE 30, 2025
In recent years, neurodegenerative disorders characterized by abnormal tau protein accumulation, collectively known as tauopathies, have posed a formidable challenge to biomedical research and clinical treatment. Alzheimer’s disease (AD) and frontotemporal lobar degeneration with tau inclusions (FTLD-tau) represent the most prominent members of this group, notoriously lacking effective therapeutic options.
STAT News
JUNE 30, 2025
AbbVie said Monday that it would pay up to $2.1 billion to acquire Capstan Therapeutics , a startup developing CAR-T therapies for autoimmune conditions, fibrosis, and cancer. AbbVie will pay up to $2.1 billion in cash when the deal closes, according to a press release. The companies did not give further details about the financial terms or a timeline for completing the acquisition.
Scienmag
JUNE 30, 2025
In the evolving landscape of biomedical materials, renewable polymers derived from natural sources have attracted significant scientific interest. The quest for sustainable and biocompatible materials has positioned polymers such as vegetable-derived cellulose, bacterial cellulose, chitosan, and starch at the forefront of cutting-edge research. These biopolymers exhibit inherent properties—including biodegradability, renewability, and minimal toxicity—that render them particularly suitable for a
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
STAT News
JUNE 30, 2025
MARSEILLE, France — When this city’s largest university launched a program earlier this year to offer U.S. scientists three-year postings, it didn’t take long for the applications to roll in. Within weeks, there were nearly 300. Those applications detailed researchers’ grants and publication records, but in the view of the president of the school, they also brought to life the very real fears American academics are facing as the Trump administration axes funding for s
Scienmag
JUNE 30, 2025
In the rapidly evolving landscape of neuroscience, Dr. Danielle Beckman, PhD, based at the University of California, Davis, is making groundbreaking strides with her meticulous use of advanced microscopy to unravel how viruses influence brain pathology. Her research is opening new frontiers in the understanding of viral impacts on neurological health, specifically examining the cellular mechanisms that underlie post-viral cognitive symptoms and neurodegeneration.
STAT News
JUNE 30, 2025
ASPEN, Colo. — When Jessica Owens was toiling away in graduate school, she didn’t know what a venture capitalist was, much less that she’d one day launch her own firm and raise its inaugural $45 million fund. Owens co-founded Initiate Ventures, a Bay Area VC firm, after a winding career that spans roles at the Centers for Disease Control and Prevention and a stint in a cancer biology Ph.D. program before she ditched the lab to explore the world of finance.
Scienmag
JUNE 30, 2025
Michael Karin, PhD, a pioneering figure in the intersection of inflammation, metabolism, and cancer biology, has embarked on a transformative new chapter in his illustrious career by joining Sanford Burnham Prebys Medical Discovery Institute. As of June 30, 2025, Karin serves as the director of the newly established Center for Metabolic and Liver Diseases.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
pharmaphorum
JUNE 30, 2025
Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.
Scienmag
JUNE 30, 2025
In the intricate ecosystem residing on human skin, a silent and relentless battle unfolds — one that profoundly shapes the microbial communities living in harmony with us. Recent advances in microbiome research have revealed that the interaction of different bacterial strains is far more complex than previously imagined. While it was understood that metabolic competition plays a role in shaping these bacterial populations, groundbreaking new research now identifies intraspecies warfare as a crit
pharmaphorum
JUNE 30, 2025
INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat
XTalks
JUNE 30, 2025
Swedish biopharma company Sobi’s Gamifant (emapalumab-lzsg) is now FDA-approved to treat hemophagocytic lymphohistiocytosis (HLH)/ macrophage activation syndrome (MAS) in both children and adults with Still’s disease — including systemic juvenile idiopathic arthritis and adult-onset Still’s disease. The approval — which is the first for treating MAS in the context of Still’s disease — covers patients who are unresponsive to or cannot tolerate glucocorticoids, or who have recurrent MAS.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Medical Xpress
JUNE 30, 2025
Mouse models are central to drug development, including treatments for neurological disorders, such as Parkinson's disease. Such diseases often affect movement, and treatments may need to relieve symptoms such as tremors. To be able to model these diseases effectively in animal studies, we need to be able to track even the smallest of movements with accuracy and precision.
STAT News
JUNE 30, 2025
WASHINGTON — The Department of Health and Human Services will renew funding to states for cancer prevention and tracking efforts, alleviating anxieties among local officials about the future of their work. Over 50 notices had gone out as of Monday, an HHS spokesperson said. The rest of the awards will be sent to states, tribes, and other contractors “no later than early next week,” press secretary Emily Hilliard told STAT in an email.
Medical Xpress
JUNE 30, 2025
Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. The study, "Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group," was published in The Lancet Oncology.
STAT News
JUNE 30, 2025
The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu. This is a tragic decision for many reasons, and also quite ironic. Perhaps the most important thing President Trump did during his first term was to invest in Operation Warp Speed, which gave us mRNA-based Covid-19 vaccines in time to save millions of lives here and around the world.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Medical Xpress
JUNE 30, 2025
Oncologists utilizing artificial intelligence (AI) in their tests to spot pancreatic cancer at an early stage can also gain an overall picture of how the deadly disease is bound to develop, scientists from the University of Sharjah have revealed in a new study.
STAT News
JUNE 30, 2025
In the summer of 2020, in the aftermath of a deadly and mysterious outbreak of a mosquito-borne disease, two prestigious universities forged a dream partnership. Virologists at the University of Texas Medical Branch in Galveston, home of the world’s largest depository of insect-borne viruses, were scrambling to understand why dozens of people in North America were dying of Eastern equine encephalitis , a disease that attacks the central nervous system.
Scienmag
JUNE 30, 2025
In a groundbreaking experimental study conducted at Oregon State University, researchers have explored the implications of feeding spent hemp biomass to dairy cows, providing crucial insights into cannabinoid absorption, distribution, and clearance. This research addresses the pivotal concern surrounding the presence of Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive compound in hemp, and its potential transfer into milk and edible tissues, a pressing issue that has so far limited the commerc
Pharmaceutical Commerce
JUNE 30, 2025
In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.
Expert insights. Personalized for you.
141 
Let's personalize your content